Dashboard
Manage Tickers

VALNValneva SE

Nasdaq valneva.com


$ 7.51 $ 0.30 (4.21 %)    

Tuesday, 30-Apr-2024 11:44:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 7.4198
$ 7.40
$ 0.00 x 0
$ 0.00 x 0
$ 7.40 - $ 7.51
$ 6.58 - $ 17.05
3,863
na
-5
$ 2.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cracking-the-code-understanding-analyst-reviews-for-valneva
Cracking The Code: Understanding Analyst R...
05/08/2024 13:00:54

hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target
HC Wainwright & Co. Reiterates Buy on Valn...
05/08/2024 10:29:49

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

valneva-for-2024-expects-total-revenues-of-170m-190m-and-rd-investments-between-60m-75m
Valneva For 2024 Expects Total Revenues Of...
05/07/2024 05:47:14

2024 financial guidance confirmed Expected total revenues between €170 million and €190 million, including: €160 million...

valneva-q1-revenue-328m-down-from-335m-yoy-net-profit-589m-up-from-net-loss-181m-yoy
Valneva Q1 Revenue €32.8M Down From €33.5M...
05/07/2024 05:46:26

Net Profit of €58.9 million, reflecting PRV sale

valneva-announces-the-initiation-of-phase-1-trial-of-second-generation-zika-vaccine-candidate
Valneva Announces The Initiation Of Phase ...
03/26/2024 07:14:09

The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to ...

what-analysts-are-saying-about-valneva-stock
What Analysts Are Saying About Valneva Stock
03/22/2024 18:01:04

guggenheim-maintains-buy-on-valneva-lowers-price-target-to-17
Guggenheim Maintains Buy on Valneva, Lower...
03/22/2024 17:59:28

Guggenheim analyst Evan Wang maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $18 to $17.

hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target
HC Wainwright & Co. Reiterates Buy on Valn...
03/21/2024 10:42:02

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

valneva-to-present-on-its-single-shot-chikungunya-vaccine-ixchiq-participate-in-multiple-events-at-the-24th-world-vaccine-congress-in-washington-dc
Valneva To Present On Its Single-Shot Chik...
03/21/2024 06:10:20

valneva-raised-2024-product-sales-guidance-to-160m-180m-prior-150m-180m-sees-total-revenues-of-170m-190m
Valneva Raised 2024 Product Sales Guidance...
03/20/2024 06:32:11

Updated FY 2024 guidance Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an ...

valneva-fy23-revenue-1537m-down-from-3613m-yoy-net-loss-1014m-compared-to-1433m-yoy
Valneva FY23 Revenue €153.7M Down From €36...
03/20/2024 06:25:29

national-cinemedia-reports-upbeat-results-joins-nordstrom-core--main-and-other-big-stocks-moving-higher-on-tuesday
National CineMedia Reports Upbeat Results,...
03/19/2024 14:03:01

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

valneva-extends-interest-only-payment-term-for-its-loan-facility-with-deerfield-and-orbimed
Valneva Extends Interest-Only Payment Term...
03/18/2024 06:43:19

Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024. Maturity of this first tr...

smith--wesson-brands-reports-upbeat-earnings-joins-americas-car-mart-hci-group-and-other-big-stocks-moving-higher-on-friday
Smith & Wesson Brands Reports Upbeat Earni...
03/08/2024 15:08:32

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target
HC Wainwright & Co. Reiterates Buy on Valn...
02/29/2024 20:03:53

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

us-centers-for-disease-control-and-preventions-advisory-committee--recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq
U.S. Centers For Disease Control And Preve...
02/29/2024 07:50:45

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ® Recommendation fo...

hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target
HC Wainwright & Co. Reiterates Buy on Valn...
02/15/2024 17:44:36

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

valnevas-2024-guidance-expects-product-sales-of-150m-180m-reflecting-continued-revenue-growth-for-proprietary-products-and-ixchiqs-launch-year-sales
Valneva's 2024 Guidance: Expects Product S...
02/15/2024 06:36:13

First full year 2024 guidance Product sales expected between €150 million and €180 million, reflecting continued revenue gro...

valnevas-2023-revenues-1537m-down-from-3613m-yoy-product-sales-grew-26-yoy-to-1446m
Valneva's 2023 Revenues €153.7M, Down From...
02/15/2024 06:33:20

Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sale...

chikungunya-vaccine-maker-valneva-secures-non-dilutive-funding-to-developexpand-its-clinical-pipeline
Chikungunya Vaccine Maker Valneva Secures ...
02/05/2024 13:55:39

Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikung...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION